Changes in serum HDL and LDL cholesterol in patients with paget’s bone disease treated with pamidronate

• Published in: Bone (New York, N.Y.) Vol. 32; no. 1; pp. 15 - 19
• Main Authors: Montagnani, A, Gonnelli, S, Cepollaro, C, Campagna, M.S, Franci, M.B, Pacini, S, Gennari, C
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2003; Elsevier Science
• Subjects: Aged; Analysis of Variance; Biological and medical sciences; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Diphosphonates - therapeutic use; Diseases of the osteoarticular system; Female; Fundamental and applied biological sciences. Psychology; Humans; Infusions, Intravenous; Lipoproteins; Male; Medical sciences; Middle Aged; Osteitis Deformans - blood; Osteitis Deformans - drug therapy; Osteoporosis. Osteomalacia. Paget disease; Paget; Pamidronate; Traumas. Diseases due to physical agents; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Paget; Pamidronate; Lipoproteins; Cholesterol; Human; Paget disease; Diseases of the osteoarticular system; Bone disease; Lipoprotein; Pamidronic acid; Treatment; Morphology; Orthopedics; Serum; Physiology

Amino bisphosphonates represent one of the most important advances in the management of Paget’s and other metabolic bone diseases. Although their mechanism of action has not yet been completely clarified, they seem to inhibit the mevalonate pathway and so they could interfere with cholesterol synthe...